Related Experiment Video

Updated: Aug 14, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Creutzfeldt-Jakob disease and the risk from blood or blood products

R G Will1, R H Kimberlin

  • 1CJD Surveillance Unit, Western General Hospital, Edinburgh, UK.

Vox Sanguinis
|December 16, 1998
PubMed

Insights

Creutzfeldt-Jakob disease (CJD) transmission via blood is unlikely for classical CJD but poses a theoretical risk for new variant CJD (nvCJD). Balancing this risk against the benefits of blood products is crucial.

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Public Health

Background:

  • Iatrogenic cases of Creutzfeldt-Jakob disease (CJD) and laboratory findings suggest potential bloodborne transmission of transmissible spongiform encephalopathies.
  • Epidemiological data for classical CJD do not strongly support transmission through blood or blood products.

Purpose of the Study:

  • To assess the theoretical risk of CJD and new variant CJD (nvCJD) transmission via blood and blood products.
  • To consider mechanisms for reducing potential transmission risks.
  • To weigh theoretical risks against established therapeutic benefits of blood products.

Main Methods:

  • Review of epidemiological evidence regarding CJD transmission.
  • Analysis of laboratory transmission studies in transmissible spongiform encephalopathies.
  • Consideration of risk mitigation strategies.

Main Results:

  • Classical CJD is not conclusively shown to be transmitted via blood.
  • New variant CJD (nvCJD) may present a higher risk of accidental transmission through blood.
  • Mechanisms to reduce theoretical risks are under evaluation.

Conclusions:

  • The risk of CJD transmission via blood requires careful consideration, particularly for nvCJD.
  • Risk management strategies are being developed to mitigate theoretical transmission risks.
  • The therapeutic benefits of blood products necessitate a balance with potential CJD transmission risks.

More Related Videos

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

Prion Safety Laboratory Swipe Test06:01

Prion Safety Laboratory Swipe Test

Published on: February 14, 2025

Related Concept Videos

Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Rh Blood Group01:19

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
Blood Transfusion01:15

Blood Transfusion

Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...